JP2019532084A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019532084A5 JP2019532084A5 JP2019520928A JP2019520928A JP2019532084A5 JP 2019532084 A5 JP2019532084 A5 JP 2019532084A5 JP 2019520928 A JP2019520928 A JP 2019520928A JP 2019520928 A JP2019520928 A JP 2019520928A JP 2019532084 A5 JP2019532084 A5 JP 2019532084A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- aryl
- compound according
- heteroaryl
- independently
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 32
- 125000000217 alkyl group Chemical group 0.000 claims 22
- 125000003118 aryl group Chemical group 0.000 claims 12
- 125000001072 heteroaryl group Chemical group 0.000 claims 11
- 229910052739 hydrogen Inorganic materials 0.000 claims 11
- 239000001257 hydrogen Substances 0.000 claims 11
- 239000000203 mixture Substances 0.000 claims 9
- 150000002431 hydrogen Chemical class 0.000 claims 8
- 125000000753 cycloalkyl group Chemical group 0.000 claims 6
- 125000000623 heterocyclic group Chemical group 0.000 claims 6
- 125000005843 halogen group Chemical group 0.000 claims 5
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- 125000006735 (C1-C20) heteroalkyl group Chemical group 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims 3
- 125000004404 heteroalkyl group Chemical group 0.000 claims 3
- 230000028993 immune response Effects 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 125000006716 (C1-C6) heteroalkyl group Chemical group 0.000 claims 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 claims 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 125000004043 oxo group Chemical group O=* 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 claims 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 2
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 claims 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims 1
- 102100037435 Antiviral innate immune response receptor RIG-I Human genes 0.000 claims 1
- 101710127675 Antiviral innate immune response receptor RIG-I Proteins 0.000 claims 1
- 108010006654 Bleomycin Proteins 0.000 claims 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims 1
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 claims 1
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 claims 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 claims 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 1
- 101001082073 Homo sapiens Interferon-induced helicase C domain-containing protein 1 Proteins 0.000 claims 1
- 102100027353 Interferon-induced helicase C domain-containing protein 1 Human genes 0.000 claims 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 1
- 101710196623 Stimulator of interferon genes protein Proteins 0.000 claims 1
- 208000000728 Thymus Neoplasms Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims 1
- 229960005305 adenosine Drugs 0.000 claims 1
- 230000005809 anti-tumor immunity Effects 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 229960001561 bleomycin Drugs 0.000 claims 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 210000003679 cervix uteri Anatomy 0.000 claims 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 1
- 229960004316 cisplatin Drugs 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 229960003901 dacarbazine Drugs 0.000 claims 1
- 229960004679 doxorubicin Drugs 0.000 claims 1
- 229960001904 epirubicin Drugs 0.000 claims 1
- 210000001508 eye Anatomy 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 229960002949 fluorouracil Drugs 0.000 claims 1
- 210000000232 gallbladder Anatomy 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- 229940029575 guanosine Drugs 0.000 claims 1
- 230000002519 immonomodulatory effect Effects 0.000 claims 1
- 230000006698 induction Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 210000001165 lymph node Anatomy 0.000 claims 1
- 229960000485 methotrexate Drugs 0.000 claims 1
- 210000000214 mouth Anatomy 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 210000003899 penis Anatomy 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 229960000487 sorafenib tosylate Drugs 0.000 claims 1
- IVDHYUQIDRJSTI-UHFFFAOYSA-N sorafenib tosylate Chemical compound [H+].CC1=CC=C(S([O-])(=O)=O)C=C1.C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 IVDHYUQIDRJSTI-UHFFFAOYSA-N 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 210000001550 testis Anatomy 0.000 claims 1
- 201000009377 thymus cancer Diseases 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- 210000004291 uterus Anatomy 0.000 claims 1
- 229960003048 vinblastine Drugs 0.000 claims 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims 1
- 229960004528 vincristine Drugs 0.000 claims 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022078657A JP2022106989A (ja) | 2016-07-06 | 2022-05-12 | 疾患の治療のための化合物、組成物、および方法 |
| JP2023162456A JP7749629B2 (ja) | 2016-07-06 | 2023-09-26 | 疾患の治療のための化合物、組成物、および方法 |
Applications Claiming Priority (17)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662359039P | 2016-07-06 | 2016-07-06 | |
| US62/359,039 | 2016-07-06 | ||
| US201662363118P | 2016-07-15 | 2016-07-15 | |
| US62/363,118 | 2016-07-15 | ||
| US201662403530P | 2016-10-03 | 2016-10-03 | |
| US62/403,530 | 2016-10-03 | ||
| US201662411424P | 2016-10-21 | 2016-10-21 | |
| US62/411,424 | 2016-10-21 | ||
| US201762444141P | 2017-01-09 | 2017-01-09 | |
| US62/444,141 | 2017-01-09 | ||
| US201762462679P | 2017-02-23 | 2017-02-23 | |
| US62/462,679 | 2017-02-23 | ||
| US201762470746P | 2017-03-13 | 2017-03-13 | |
| US62/470,746 | 2017-03-13 | ||
| US201762508846P | 2017-05-19 | 2017-05-19 | |
| US62/508,846 | 2017-05-19 | ||
| PCT/US2017/040882 WO2018009648A1 (en) | 2016-07-06 | 2017-07-06 | Compounds, compositions, and methods for the treatment of disease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022078657A Division JP2022106989A (ja) | 2016-07-06 | 2022-05-12 | 疾患の治療のための化合物、組成物、および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019532084A JP2019532084A (ja) | 2019-11-07 |
| JP2019532084A5 true JP2019532084A5 (https=) | 2020-08-06 |
| JP7100227B2 JP7100227B2 (ja) | 2022-07-13 |
Family
ID=60913147
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019520928A Active JP7100227B2 (ja) | 2016-07-06 | 2017-07-06 | 疾患の治療のための化合物、組成物、および方法 |
| JP2022078657A Pending JP2022106989A (ja) | 2016-07-06 | 2022-05-12 | 疾患の治療のための化合物、組成物、および方法 |
| JP2023162456A Active JP7749629B2 (ja) | 2016-07-06 | 2023-09-26 | 疾患の治療のための化合物、組成物、および方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022078657A Pending JP2022106989A (ja) | 2016-07-06 | 2022-05-12 | 疾患の治療のための化合物、組成物、および方法 |
| JP2023162456A Active JP7749629B2 (ja) | 2016-07-06 | 2023-09-26 | 疾患の治療のための化合物、組成物、および方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11033569B2 (https=) |
| EP (1) | EP3481402A4 (https=) |
| JP (3) | JP7100227B2 (https=) |
| KR (1) | KR102569881B1 (https=) |
| CN (1) | CN109843302B (https=) |
| AU (1) | AU2017293781B2 (https=) |
| CA (1) | CA3029644A1 (https=) |
| IL (1) | IL264049B2 (https=) |
| MX (2) | MX392605B (https=) |
| MY (1) | MY199689A (https=) |
| SG (1) | SG11201811709WA (https=) |
| TW (1) | TWI689514B (https=) |
| WO (1) | WO2018009648A1 (https=) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201912074PA (en) | 2016-03-18 | 2020-02-27 | Immune Sensor Llc | Cyclic di-nucleotide compounds and methods of use |
| US11033569B2 (en) * | 2016-07-06 | 2021-06-15 | Sperovie Biosciences, Inc. | Compounds,Compositions, and methods for the treatment of disease |
| WO2018100558A2 (en) | 2016-12-01 | 2018-06-07 | Takeda Pharmaceutical Company Limited | Cyclic dinucleotide |
| CN118267470A (zh) | 2017-04-13 | 2024-07-02 | 赛罗帕私人有限公司 | 抗SIRPα抗体 |
| AR113224A1 (es) | 2017-04-28 | 2020-02-19 | Novartis Ag | Conjugados de anticuerpo que comprenden un agonista de sting |
| JP7195317B2 (ja) | 2017-11-10 | 2022-12-23 | 武田薬品工業株式会社 | Ｓｔｉｎｇ調節剤化合物、ならびに製造及び使用する方法 |
| CN111511754B (zh) | 2017-12-20 | 2023-09-12 | 捷克共和国有机化学与生物化学研究所 | 活化sting转接蛋白的具有膦酸酯键的2’3’环状二核苷酸 |
| US10966999B2 (en) | 2017-12-20 | 2021-04-06 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | ２，２，─環二核苷酸 |
| WO2019211799A1 (en) | 2018-05-03 | 2019-11-07 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide |
| EP3820477A4 (en) | 2018-07-10 | 2022-07-13 | Sperovie Biosciences, Inc. | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES |
| TW202030199A (zh) * | 2018-07-17 | 2020-08-16 | 美商健生生物科技公司 | 作為ｓｔｉｎｇ促效劑之環狀二核苷酸 |
| KR102567590B1 (ko) | 2018-09-06 | 2023-08-17 | 다이이찌 산쿄 가부시키가이샤 | 신규 고리형 디뉴클레오티드 유도체 및 그 항체 약물 콘쥬게이트 |
| AU2019344398B2 (en) | 2018-09-21 | 2022-09-22 | Shanghai De Novo Pharmatech Co., Ltd. | Cyclic dinucleotide analogue, pharmaceutical composition thereof, and application |
| US11110106B2 (en) | 2018-10-29 | 2021-09-07 | Venenum Biodesign, LLC | Sting agonists for treating bladder cancer and solid tumors |
| AU2019371206A1 (en) | 2018-10-29 | 2021-05-27 | Venenum Biodesign, LLC | Novel sting agonists |
| WO2020092617A1 (en) | 2018-10-31 | 2020-05-07 | Novartis Ag | Dc-sign antibody conjugates comprising sting agonists |
| KR102620495B1 (ko) * | 2019-01-10 | 2024-01-04 | 셴젠 잉 바이오파마수티칼 씨오., 엘티디. | 시클릭 디뉴클레오티드 프로드러그 분자 및 이의 제조 방법과 응용 |
| US11766447B2 (en) | 2019-03-07 | 2023-09-26 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
| EP3935066A1 (en) * | 2019-03-07 | 2022-01-12 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 3'3'-cyclic dinucleotides and prodrugs thereof |
| KR102707808B1 (ko) | 2019-03-07 | 2024-09-19 | 인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이. | 2'3'-사이클릭 다이뉴클레오티드 및 이의 프로드럭 |
| JP7621974B2 (ja) | 2019-05-09 | 2025-01-27 | アリゴス セラピューティクス インコーポレイテッド | Ｓｔｉｎｇモジュレータとしての修飾環状ジヌクレオシド化合物 |
| AU2020310853A1 (en) | 2019-07-05 | 2022-01-27 | Tambo, Inc. | Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy |
| CA3168368A1 (en) | 2020-03-06 | 2021-09-10 | Masayuki Ishizaki | Antibody-drug conjugate including novel cyclic dinucleotide derivative |
| WO2021206158A1 (ja) | 2020-04-10 | 2021-10-14 | 小野薬品工業株式会社 | がん治療方法 |
| CN111909223A (zh) * | 2020-07-17 | 2020-11-10 | 清华大学 | 环二核苷酸共价修饰物及其制备方法和应用 |
| EP4295917A3 (en) | 2020-08-07 | 2024-02-28 | Tambo, Inc. | Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy |
| TW202227479A (zh) | 2020-09-02 | 2022-07-16 | 日商第一三共股份有限公司 | 新穎內－β－Ｎ－乙醯葡萄糖胺苷酶 |
| JP7397996B2 (ja) | 2020-11-09 | 2023-12-13 | 武田薬品工業株式会社 | 抗体薬物コンジュゲート |
| US20250207169A1 (en) | 2022-03-02 | 2025-06-26 | Daiichi Sankyo Company, Limited | METHOD FOR PRODUCING Fc-CONTAINING MOLECULE |
| AU2023336004A1 (en) | 2022-08-29 | 2025-03-06 | Daiichi Sankyo Company, Limited | Antibody-drug conjugate including mutant fc region |
| WO2024076728A1 (en) * | 2022-10-06 | 2024-04-11 | Dana-Farber Cancer Institute, Inc. | Cyclic nucleotides and uses thereof |
| WO2026027944A1 (en) | 2024-07-30 | 2026-02-05 | Sairopa B.V. | Anti-sirp alpha antibody formulations and uses thereof |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2257704B (en) * | 1991-07-18 | 1995-03-01 | Erba Carlo Spa | Cyclic oligonucleotides phosphorothioates |
| MXPA05013658A (es) * | 2003-06-11 | 2006-03-02 | Hybridon Inc | Oligonucleotidos inmunomoduladores estabilizados. |
| US7592326B2 (en) * | 2004-03-15 | 2009-09-22 | Karaolis David K R | Method for stimulating the immune, inflammatory or neuroprotective response |
| EP1729781B1 (en) * | 2004-03-15 | 2012-10-24 | Karaolis, David K. R. | A method for inhibiting cancer cell proliferation or increasing cancer cell apoptosis |
| US20120178710A1 (en) * | 2009-07-01 | 2012-07-12 | Rutgers, The State University Of New Jersey | Synthesis of cyclic diguanosine monophosphate and thiophosphate analogs thereof |
| CN102199183B (zh) * | 2010-03-26 | 2013-12-18 | 北京大学 | 环二鸟苷酸及其类似物和制备方法 |
| CN104507538B (zh) | 2012-06-08 | 2018-04-06 | 艾杜罗生物科技公司 | 癌症免疫疗法的组合物和方法 |
| PL2931738T3 (pl) | 2012-12-13 | 2019-07-31 | Aduro Biotech, Inc. | Kompozycje zawierające cykliczne dinukleotydy purynowe o zdefiniowanej stereochemii i sposoby ich otrzymywania i zastosowania |
| PT2934598T (pt) * | 2012-12-19 | 2018-07-24 | Univ Texas | Focalização farmacêutica de uma trajetória de sinalização de dinucleótido cíclico de mamífero |
| WO2014098865A1 (en) * | 2012-12-20 | 2014-06-26 | Hill's Pet Nutrition, Inc. | Pattern recognition receptor expression as a measure of systemic health |
| JP6153116B2 (ja) * | 2013-01-09 | 2017-06-28 | 国立大学法人東北大学 | トリアゾール連結型環状ジヌクレオチド類縁体 |
| EP2762154A3 (en) * | 2013-02-05 | 2015-01-21 | Nitto Denko Corporation | Vaccine composition for transdermal administration |
| WO2014179760A1 (en) | 2013-05-03 | 2014-11-06 | The Regents Of The University Of California | Cyclic di-nucleotide induction of type i interferon |
| RS59500B1 (sr) | 2013-05-18 | 2019-12-31 | Aduro Biotech Inc | Sastavi i metode za aktiviranje signaliziranja koje je zavisno od „stimulatora gena za interferon“ |
| CN103864910B (zh) * | 2014-03-03 | 2016-01-20 | 中国科学院南海海洋研究所 | 一种新型特异结合lps的贝类模式识别受体lrrp |
| AU2015228372B2 (en) | 2014-03-12 | 2018-05-31 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
| PE20170198A1 (es) | 2014-06-04 | 2017-04-08 | Glaxosmithkline Ip Dev Ltd | Dinucleotidos ciclicos como moduladores de sting |
| WO2016096577A1 (en) | 2014-12-16 | 2016-06-23 | Invivogen | Combined use of a chemotherapeutic agent and a cyclic dinucleotide for cancer treatment |
| EP3546473B1 (en) * | 2014-12-16 | 2025-12-10 | Kayla Therapeutics | Fluorinated cyclic [(2',5')p(3',5')p]-dinucleotides for cytokine induction |
| GB201501462D0 (en) | 2015-01-29 | 2015-03-18 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| HK1248603A1 (zh) * | 2015-03-10 | 2018-10-19 | Aduro Biotech, Inc. | 用於活化"干扰素基因的刺激剂"依懒性信号传导的组合物和方法 |
| CR20180101A (es) | 2015-08-13 | 2018-04-12 | Merck Sharp & Dohme | Compuestos di-nucleóticos cíclicos como agonistas de sting |
| CA3002236A1 (en) | 2015-10-28 | 2017-05-04 | Aduro Biotech, Inc. | Compositions and methods for activating "stimulator of interferon gene"-dependent signalling |
| TWI704154B (zh) | 2015-12-03 | 2020-09-11 | 英商葛蘭素史克智慧財產發展有限公司 | 新穎化合物 |
| CN106540260A (zh) | 2015-12-09 | 2017-03-29 | 聊城市奥润生物医药科技有限公司 | 干扰素基因刺激蛋白（sting）激动剂在抗阿尔兹海默症中的应用 |
| US20180369268A1 (en) * | 2015-12-16 | 2018-12-27 | Aduro Biotech, Inc. | Methods for identifying inhibitors of "stimulator of interferon gene"- dependent interferon production |
| WO2017123657A1 (en) | 2016-01-11 | 2017-07-20 | Gary Glick | Cyclic dinucleotides for treating conditions associated with sting activity such as cancer |
| RS67188B1 (sr) | 2016-01-11 | 2025-10-31 | Innate Tumor Immunity Inc | Ciklični dinukleotidi za lečenje stanja povezanih sa aktivnošću sting kao što je kancer |
| MX2018010586A (es) | 2016-03-02 | 2019-03-28 | Univ Texas | Nanovacuna de activacion de "sting" para inmunoterapia. |
| WO2018009466A1 (en) | 2016-07-05 | 2018-01-11 | Aduro Biotech, Inc. | Locked nucleic acid cyclic dinucleotide compounds and uses thereof |
| US11033569B2 (en) * | 2016-07-06 | 2021-06-15 | Sperovie Biosciences, Inc. | Compounds,Compositions, and methods for the treatment of disease |
| US20190345191A1 (en) | 2016-08-31 | 2019-11-14 | Innate Tumor Immunity, Inc. | Cyclic dinucleotide analogs for treating conditions associated with sting (stimulator of interferon genes) activity |
| US10414747B2 (en) | 2016-10-04 | 2019-09-17 | Merck Sharp & Dohme Corp. | Benzo[b]thiophene compounds as sting agonists |
| WO2018100558A2 (en) | 2016-12-01 | 2018-06-07 | Takeda Pharmaceutical Company Limited | Cyclic dinucleotide |
| WO2018118665A1 (en) | 2016-12-20 | 2018-06-28 | Merck Sharp & Dohme Corp. | Cyclic dinucleotide sting agonists for cancer treatment |
| CA3047394A1 (en) | 2016-12-20 | 2018-06-28 | Merck Sharp & Dohme Corp. | Combinations of pd-1 antagonists and cyclic dinucleotide sting agonists for cancer treatment |
| CA3053568A1 (en) | 2017-02-21 | 2018-08-30 | Board Of Regents, The University Of Texas System | Cyclic dinucleotides as agonists of stimulator of interferon gene dependent signalling |
| UY37695A (es) | 2017-04-28 | 2018-11-30 | Novartis Ag | Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo |
| US11466047B2 (en) | 2017-05-12 | 2022-10-11 | Merck Sharp & Dohme Llc | Cyclic di-nucleotide compounds as sting agonists |
| JP2020524718A (ja) | 2017-06-22 | 2020-08-20 | キュラデブ・ファーマ・リミテッドＣｕｒａｄｅｖ Ｐｈａｒｍａ Ｌｉｍｉｔｅｄ | ヒトｓｔｉｎｇの複素環式小分子調節因子 |
| PE20200696A1 (es) | 2017-06-22 | 2020-06-16 | Curadev Pharma Ltd | Moduladores de moleculas pequenas de sting humana |
| US20200138827A1 (en) | 2017-06-22 | 2020-05-07 | Curadev Pharma Limited | Small molecule modulators of human sting |
| WO2019051489A1 (en) * | 2017-09-11 | 2019-03-14 | Sperovie Biosciences, Inc. | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISEASE |
-
2017
- 2017-07-06 US US16/315,472 patent/US11033569B2/en active Active
- 2017-07-06 TW TW106122757A patent/TWI689514B/zh active
- 2017-07-06 CA CA3029644A patent/CA3029644A1/en active Pending
- 2017-07-06 CN CN201780054031.7A patent/CN109843302B/zh active Active
- 2017-07-06 JP JP2019520928A patent/JP7100227B2/ja active Active
- 2017-07-06 MX MX2019000216A patent/MX392605B/es unknown
- 2017-07-06 MY MYPI2019000212A patent/MY199689A/en unknown
- 2017-07-06 EP EP17824876.1A patent/EP3481402A4/en active Pending
- 2017-07-06 WO PCT/US2017/040882 patent/WO2018009648A1/en not_active Ceased
- 2017-07-06 IL IL264049A patent/IL264049B2/en unknown
- 2017-07-06 AU AU2017293781A patent/AU2017293781B2/en active Active
- 2017-07-06 KR KR1020197003440A patent/KR102569881B1/ko active Active
- 2017-07-06 SG SG11201811709WA patent/SG11201811709WA/en unknown
-
2019
- 2019-01-07 MX MX2022006260A patent/MX2022006260A/es unknown
-
2021
- 2021-06-04 US US17/339,484 patent/US11744845B2/en active Active
-
2022
- 2022-05-12 JP JP2022078657A patent/JP2022106989A/ja active Pending
-
2023
- 2023-09-26 JP JP2023162456A patent/JP7749629B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019532084A5 (https=) | ||
| JP2020532532A5 (https=) | ||
| JP2015518899A5 (https=) | ||
| JP2016514719A5 (https=) | ||
| JP2017071634A5 (https=) | ||
| RU2015143717A (ru) | 2-Аминопиримидин-6-оны и аналоги, проявляющие противораковые и антипролиферативные действия | |
| JP2018516888A5 (https=) | ||
| JP2018109050A5 (https=) | ||
| JP2016503799A5 (https=) | ||
| JP2016523269A5 (https=) | ||
| JP2018515438A5 (https=) | ||
| JP2017526677A5 (https=) | ||
| JP2016519653A5 (https=) | ||
| JP2014510147A5 (https=) | ||
| JP2018529739A5 (https=) | ||
| JP2015537017A5 (https=) | ||
| JP2016121196A5 (https=) | ||
| JP2021522166A5 (https=) | ||
| RU2016115082A (ru) | Замещенные аминопиримидиновые соединения и способы их использования | |
| JP2013522292A5 (https=) | ||
| SI2935248T1 (en) | Compounds and procedures for kinase modulation and indications for the latter | |
| JP2017514910A5 (https=) | ||
| JP2016530259A5 (https=) | ||
| JP2018516963A5 (https=) | ||
| JP2017517565A5 (https=) |